Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus –Infected Subjects

Maurer, Toby; Poncelet, Ann; Berger, Timothy G.

doi:10.1001/archderm.140.7.845

Cited by 56 publications

(19 citation statements)

References 45 publications

(58 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is useful in prurigo nodularis and uremic pruritus (Maurer et al 2004). Thalidomide is teratogenic with a risk of neuropathy; therefore, it is not recommended routinely for the treatment of chronic pruritus and is used for limited durations of up to 1 year.…”

Section: Thalidomidementioning

confidence: 99%

Current Topical and Systemic Therapies for Itch

Leslie

Greaves

Yosipovitch

2015

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

Itch is a common distressing symptom which may be caused by multifactorial aetiologies including inflammatory skin diseases, systemic diseases, neuropathic conditions and psychogenic disorders. Itch is a term used synonymously with pruritus and is defined as acute if it lasts less than 6 weeks or chronic if it persists for more than 6 weeks. It can have the same impact on the quality of life as chronic pain and shares many of the same pathophysiological pathways. Depending on the aetiology of the itch, different pathogenic mechanisms have been postulated with a number of mediators identified. These include histamine, leukotrienes, proteases, neuropeptides, cytokines and opioids, which may activate peripheral itch-mediating C-fibres via receptors on the nerve terminals and central neuronal pathways. Therefore, there is no single universally effective anti-itch treatment available. First-line treatments for itch include topical therapies, such as emollients, mild cleansers (low pH), topical anaesthetics, steroids, calcineurin inhibitors and coolants (menthol). Treatment with systemic therapies can vary according to the aetiology of the chronic itch. Non-sedating antihistamines are helpful in conditions such as urticaria where the itch is primarily histamine mediated. Although the itch of eczema is not mediated by histamine, sedating antihistamines at night are helpful to break the itch-scratch cycle. Chronic itch may also be treated with other systemic therapies, such as anticonvulsants, antidepressants as well as mu-opioid antagonists, kappa-opioid agonists and phototherapy, depending on the cause of the itch. This article summarises the topical and systemic therapies available with our current understanding of the pathophysiology of itch.

show abstract

Section: Thalidomidementioning

confidence: 99%

Current Topical and Systemic Therapies for Itch

Leslie

Greaves

Yosipovitch

2015

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

show abstract

“…Thalidomide has been used as a treatment for various HIVassociated illnesses, mainly for the occasional complication of a severe, refractory inflammatory reaction, as occurs in patients with major oral and esophageal aphthous ulceration [1,2], hypertrophic mucocutaneous herpes simplex [3], and prurigo nodularis [4]. It has also been used to treat HIV-related malignancies (e.g., Kaposi sarcoma [5] and Castleman disease) and other chronic HIV-related illness (e.g., wasting [6] and chronic enteropathy).…”

Section: Thalidomide Has Been Used As a Treatment For Various Human Imentioning

confidence: 99%

“…All 4 studies reported mild-to-moderate adverse effects (mainly rash, somnolence, and sensory peripheral neuropathy). Other case reports have described the beneficial use of thalidomide in HIV-infected patients with alopecia areata, hypertrophic genital herpes infection [3], prurigo nodularis [4], Kaposi sarcoma [10], and Castleman disease.…”

Section: Thalidomide Has Been Used As a Treatment For Various Human Imentioning

confidence: 99%

Thalidomide Treatment for Refractory HIV‐Associated Colitis: A Case Series

et al. 2008

View full text Add to dashboard Cite

show abstract

“…8 These immunological effects of thalidomide could be responsible for the objective clinical response noted at 8 weeks of therapy. However, in view of the toxicity of thalidomide, [9][10][11][12] lower doses of thalidomide may be more appropriate. The immunomodulatory role of thalidomide in the treatment of MF deserves further study, particularly in view of the objective clinical response noted at 8 weeks in our patient, when all previous therapies had failed.…”

Section: Thalidomide In Mycosis Fungoidesmentioning

confidence: 99%